scholarly journals Bloodstream infection antibiogram in Syrian febrile neutropenic patients

2020 ◽  
Vol 101 ◽  
pp. 26
Author(s):  
A. Alrstom ◽  
N. Daher ◽  
R. Abouharb
Keyword(s):  
Bloodstream Infection ◽  
Neutropenic Patients

scholarly journals Frequency of bloodstream infection in febrile neutropenic patients, experience from a developing country

2018 ◽  
Vol 34 ◽  
pp. 71-74
Author(s):  
Basit Siddiqui ◽  
Rabeea Azmat ◽  
Shiyam Sunder Tikmani ◽  
Shumaila Rafi ◽  
Beenish Syed ◽  
...  
Keyword(s):  
Bloodstream Infection ◽  
Developing Country ◽  
Neutropenic Patients ◽  
Patients Experience

scholarly journals Efficacy of β-Lactam/β-Lactamase Inhibitor Combinations for the Treatment of Bloodstream Infection Due to Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae in Hematological Patients with Neutropenia

2017 ◽  
Vol 61 (8) ◽  
Author(s):  
Carlota Gudiol ◽  
Cristina Royo-Cebrecos ◽  
Edson Abdala ◽  
Murat Akova ◽  
Rocío Álvarez ◽  
...  
Keyword(s):  
Bloodstream Infection ◽  
Case Fatality ◽  
Empirical Therapy ◽  
Day Case ◽  
Hematological Patients ◽  
Extended Spectrum ◽  
Definitive Therapy ◽  
Neutropenic Patients ◽  
Secondary Outcomes ◽  
Lactamase Inhibitor

ABSTRACT β-Lactam/β-lactamase inhibitors (BLBLIs) were compared to carbapenems in two cohorts of hematological neutropenic patients with extended-spectrum-β-lactamase (ESBL) bloodstream infection (BSI): the empirical therapy cohort (174 patients) and the definitive therapy cohort (251 patients). The 30-day case fatality rates and other secondary outcomes were similar in the two therapy groups of the two cohorts and also in the propensity-matched cohorts. BLBLIs might be carbapenem-sparing alternatives for the treatment of BSI due to ESBLs in these patients.

scholarly journals 2675. Changing Epidemiology of Bloodstream Infection During Chemotherapy for Acute Leukemia: Impact of Prophylactic Fluoroquinolone Restriction and Carbapenem Saving Strategy

2019 ◽  
Vol 6 (Supplement_2) ◽  
pp. S938-S939
Author(s):  
Yunmi Yi ◽  
Sung-Yeon Cho ◽  
Dong-Gun Lee ◽  
Jae-Ki Choi ◽  
Hyo-Jin Lee ◽  
...  
Keyword(s):  
Septic Shock ◽  
Febrile Neutropenia ◽  
Acute Leukemia ◽  
Bloodstream Infection ◽  
Remission Induction ◽  
Period 2 ◽  
Defined Daily Doses ◽  
Neutropenic Patients ◽  
The Impact ◽  
Fluoroquinolone Prophylaxis

Abstract Background Fluoroquinolone prophylaxis has been widely used in high-risk neutropenic patients with hematological malignancies, which may reduce bloodstream infection (BSI) and mortality. However, concerns about antibiotic resistance also exist. The aim of this study was to assess the impact of new institutional strategy of restricting fluoroquinolone prophylaxis and saving carbapenem, applied since October 2016. Fluoroquinolone prophylaxis was adopted only in remission induction chemotherapy, and carbapenems were saved until other antibiotics prove no effectiveness Methods We retrospectively reviewed all consecutive intensive chemotherapy episodes for acute leukemia from April 2016 to March 2017 at the Catholic Hematology Hospital. In addition, antibiotics consumption was assessed by calculating defined daily doses (DDDs) per 100 bed-days. Results Among 420 admissions during the study period, 201 and 219 admissions were identified before (period 1) and after (period 2) the strategy modification. Baseline characteristics including types of leukemia, chemotherapy, severity and duration of neutropenia were not different between the two periods.Development of febrile neutropenia (83.6% vs. 84.0%, P = 0.487), BSI (46.3% vs. 52.5%, P = 0.291), and septic shock (4.0% vs. 6.4%, P = 0.268) were not significantly different. Polymicrobial BSI increased significantly (7.1% vs. 20.0%, p = 0.012) in period 2. Quinolone resistance (97.8% vs. 43.6%, P < 0.001) and extended-spectrum β-lactamase producers (50% vs. 29.1%, P = 0.032) among Enterobacteriaceae were significantly reduced. Carbapenem-resistant Enterobacteriaceae was not isolated in period 2. Vancomycin resistance among enterococci (66.7% vs. 15%, P = 0.006) decreased. Consumption of ciprofloxacin (37.2 vs. 13.8) and carbapenem (22.3 vs. 16.8) decreased, while piperacillin/tazobactam consumption increased (5.2 vs. 13.0). BSI-related death (1.0% vs. 0.9%) was not increased. Conclusion Fluoroquinolone prophylaxis restriction and carbapenem saving strategies resulted in significant reduction of resistant bacterial BSIs, without increase in febrile neutropenia, BSI, septic shock, and BSI-related death. Antibiotics stewardship program can be tried in neutropenic patients, which may improve the ultimate outcome. Disclosures All authors: No reported disclosures.

scholarly journals Predictors of multidrug-resistant Pseudomonas aeruginosa in neutropenic patients with bloodstream infection

2020 ◽  
Vol 26 (3) ◽  
pp. 345-350 ◽  
Author(s):  
D. Viasus ◽  
P. Puerta-Alcalde ◽  
C. Cardozo ◽  
M. Suárez-Lledó ◽  
O. Rodríguez-Núñez ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Bloodstream Infection ◽  
Multidrug Resistant ◽  
Neutropenic Patients

Intravascular catheter-related bloodstream infection caused by Abiotrophia defectiva in a neutropenic child

2013 ◽  
Vol 62 (5) ◽  
pp. 789-791 ◽  
Author(s):  
A. Phulpin-Weibel ◽  
N. Gaspar ◽  
A. Emirian ◽  
E. Chachaty ◽  
D. Valteau-Couanet ◽  
...  
Keyword(s):  
Bloodstream Infection ◽  
Langerhans Cell Histiocytosis ◽  
Rare Case ◽  
Venous Catheter ◽  
Febrile Child ◽  
Intravascular Catheter ◽  
Abiotrophia Defectiva ◽  
Neutropenic Patients ◽  
Catheter Related Bloodstream Infection

Bacteraemia and endocarditis are the most frequently reported clinical infections due to Abiotrophia defectiva species. This species has been rarely implicated in infections in neutropenic patients. We report a rare case of long-term venous catheter-related infection caused by A. defectiva that occurred in a febrile child who had neutropenia and Langerhans’ cell histiocytosis.

scholarly journals Clinical Predictive Model of Multidrug Resistance in Neutropenic Cancer Patients with Bloodstream Infection Due to Pseudomonas aeruginosa

2020 ◽  
Vol 64 (4) ◽  
Author(s):  
C. Gudiol ◽  
A. Albasanz-Puig ◽  
J. Laporte-Amargós ◽  
N. Pallarès ◽  
A. Mussetti ◽  
...  
Keyword(s):  
Pseudomonas Aeruginosa ◽  
Multidrug Resistance ◽  
Cancer Patients ◽  
Bloodstream Infection ◽  
Broad Spectrum ◽  
Multidrug Resistant ◽  
Content Type ◽  
Prior Therapy ◽  
Simple Strategy ◽  
Neutropenic Patients

ABSTRACT We aimed to assess the rate and predictive factors of bloodstream infection (BSI) due to multidrug-resistant (MDR) Pseudomonas aeruginosa in neutropenic cancer patients. We performed a multicenter, retrospective cohort study including oncohematological neutropenic patients with BSI due to P. aeruginosa conducted across 34 centers in 12 countries from January 2006 to May 2018. A mixed logistic regression model was used to estimate a model to predict the multidrug resistance of the causative pathogens. Of a total of 1,217 episodes of BSI due to P. aeruginosa, 309 episodes (25.4%) were caused by MDR strains. The rate of multidrug resistance increased significantly over the study period (P = 0.033). Predictors of MDR P. aeruginosa BSI were prior therapy with piperacillin-tazobactam (odds ratio [OR], 3.48; 95% confidence interval [CI], 2.29 to 5.30), prior antipseudomonal carbapenem use (OR, 2.53; 95% CI, 1.65 to 3.87), fluoroquinolone prophylaxis (OR, 2.99; 95% CI, 1.92 to 4.64), underlying hematological disease (OR, 2.09; 95% CI, 1.26 to 3.44), and the presence of a urinary catheter (OR, 2.54; 95% CI, 1.65 to 3.91), whereas older age (OR, 0.98; 95% CI, 0.97 to 0.99) was found to be protective. Our prediction model achieves good discrimination and calibration, thereby identifying neutropenic patients at higher risk of BSI due to MDR P. aeruginosa. The application of this model using a web-based calculator may be a simple strategy to identify high-risk patients who may benefit from the early administration of broad-spectrum antibiotic coverage against MDR strains according to the local susceptibility patterns, thus avoiding the use of broad-spectrum antibiotics in patients at a low risk of resistance development.

Sign in / Sign up

Export Citation Format

Share Document